ILTOO PHARMA SAS announces the initiation of Managed Access Programs for the compassionate treatment of patients afflicted with Amyotrophic Lateral Sclerosis (ALS) with ILT-101, the company’s lead drug.
ILTOO PHARMA SAS announces the initiation of Managed Access Programs for the compassionate treatment of patients afflicted with Amyotrophic Lateral Sclerosis (ALS) with ILT-101, the company’s lead drug.